Bulletin
Investor Alert

New York Markets After Hours

Pacira BioSciences Inc.

NAS: PCRX

GO
/marketstate/country/us

After Hours

 --Real time quotes

Oct 21, 2021, 4:54 p.m.

/zigman2/quotes/202929053/composite

$

53.12

Change

0.00 0.00%

Volume

Volume 2,575

Real time quotes

/zigman2/quotes/202929053/composite

Today's close

$ 53.11

$ 53.12

Change

+0.01 +0.02%

Day low

Day high

$52.73

$53.51

Open

52 week low

52 week high

$45.05

$80.00

Open

Company Description

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in P...

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Parsippany, NJ.

Valuation

P/E Current

15.94

P/E Ratio (with extraordinary items)

13.91

P/E Ratio (without extraordinary items)

17.96

Price to Sales Ratio

6.08

Price to Book Ratio

4.21

Price to Cash Flow Ratio

33.93

Enterprise Value to EBITDA

35.77

Enterprise Value to Sales

6.13

Total Debt to Enterprise Value

0.21

Efficiency

Revenue/Employee

688,537.00

Income Per Employee

233,210.00

Receivables Turnover

8.54

Total Asset Turnover

0.41

Liquidity

Current Ratio

2.57

Quick Ratio

2.32

Cash Ratio

2.06

Profitability

Gross Margin

70.86

Operating Margin

11.99

Pretax Margin

4.68

Net Margin

33.87

Return on Assets

13.82

Return on Equity

29.86

Return on Total Capital

5.52

Return on Invested Capital

17.06

Capital Structure

Total Debt to Total Equity

87.32

Total Debt to Total Capital

46.62

Total Debt to Total Assets

42.46

Long-Term Debt to Equity

61.98

Long-Term Debt to Total Capital

33.08

Officers and Executives

Name Age Officer Since Title
Mr. David M. Stack 68 2007 President & Chief Executive Officer
Mr. Charles A. Reinhart 59 2011 Chief Financial Officer
Mr. Charles Anthony Laranjeira 54 2017 Chief Technical Officer
Dr. Roy Winston 59 2017 Chief Clinical Officer
Dr. Jonathan Slonin - 2020 Chief Clinical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/03/2021 Roy Winston
Chief Medical Officer
5,000   Award at $0 per share. 0
08/03/2021 Jonathan Slonin
Chief Clinical Officer
5,000   Award at $0 per share. 0
07/29/2021 Lauren Bullaro Riker
Vice President, Finance
90   Disposition at $60.81 per share. 5,472
07/29/2021 Lauren Bullaro Riker
Vice President, Finance
90   Derivative/Non-derivative trans. at $10.81 per share. 972
07/28/2021 Lauren Bullaro Riker
Vice President, Finance
2,410   Disposition at $60.85 per share. 146,648
07/28/2021 Lauren Bullaro Riker
Vice President, Finance
2,410   Derivative/Non-derivative trans. at $10.81 per share. 26,052
07/02/2021 Max Reinhardt
President, Rest of World
421   Disposition at $59.76 per share. 25,158
06/11/2021 Lauren Bullaro Riker
Vice President, Finance
2,003   Disposition at $59.85 per share. 119,879
06/10/2021 Kristen Marie Williams
Chief Administrative Officer
847   Disposition at $60.57 per share. 51,302
06/10/2021 Kristen Marie Williams
Chief Administrative Officer
4,842   Disposition at $59.43 per share. 287,760
06/09/2021 David M. Stack
CEO and Chairman; Director
17,800   Award at $0 per share. 0
06/09/2021 Gary W. Pace
Director
1,066   Award at $0 per share. 0
06/09/2021 Roy Winston
Chief Medical Officer
7,000   Award at $0 per share. 0
06/09/2021 Dennis Mcloughlin
Chief Customer Officer
6,000   Award at $0 per share. 0
06/09/2021 Charles A. Reinhart
Chief Financial Officer
6,000   Award at $0 per share. 0
06/09/2021 Donald C. Manning
Chief Medical Officer
6,000   Award at $0 per share. 0
06/09/2021 Charles Anthony Laranjeira
Chief Technical Officer
7,000   Award at $0 per share. 0
06/09/2021 Kristen Marie Williams
Chief Administrative Officer
7,000   Award at $0 per share. 0
06/09/2021 John P. Longenecker
Director
1,066   Award at $0 per share. 0
06/09/2021 Max Reinhardt
President, Rest of World
7,000   Award at $0 per share. 0
06/09/2021 Mark A. Kronenfeld
Director
1,066   Award at $0 per share. 0
06/09/2021 Lauren Bullaro Riker
Vice President, Finance
2,600   Award at $0 per share. 0
06/09/2021 Yvonne L. Greenstreet
Director
1,066   Award at $0 per share. 0
06/09/2021 Laura A. Brege
Director
1,066   Award at $0 per share. 0
06/09/2021 Paul J. Hastings
Director
1,066   Award at $0 per share. 0
06/09/2021 Mark I. Froimson
Director
1,066   Award at $0 per share. 0
06/09/2021 Christopher J. Christie
Director
1,066   Award at $0 per share. 0
06/08/2021 Donald C. Manning
Chief Medical Officer
2,600   Disposition at $61.14 per share. 158,964
06/07/2021 Max Reinhardt
President, Rest of World
2,278   Disposition at $60.5 per share. 137,819
06/04/2021 David M. Stack
CEO and Chairman; Director
14,905   Disposition at $61.04 per share. 909,801
06/04/2021 Roy Winston
Chief Medical Officer
2,276   Disposition at $61.04 per share. 138,927
06/04/2021 Dennis Mcloughlin
Chief Customer Officer
1,895   Disposition at $61.04 per share. 115,670
06/04/2021 Charles A. Reinhart
Chief Financial Officer
2,648   Disposition at $61.04 per share. 161,633
06/04/2021 Charles Anthony Laranjeira
Chief Technical Officer
2,117   Disposition at $61.04 per share. 129,221
06/04/2021 Kristen Marie Williams
Chief Administrative Officer
3,930   Disposition at $61.04 per share. 239,887
06/04/2021 Max Reinhardt
President, Rest of World
1,222   Disposition at $61.04 per share. 74,590
06/04/2021 Lauren Bullaro Riker
Vice President, Finance
1,047   Disposition at $61.04 per share. 63,908
06/04/2021 Paul J. Hastings
Director
630   Disposition at $62.19 per share. 39,179
/news/latest/company/us/pcrx

MarketWatch News on PCRX

  1. Pacira Biosciences to acquire Flexion Therapeutics for $8.50 a share in cash, pulse CVR worth up to $8 a share

    7:03 a.m. Oct. 11, 2021

    - Ciara Linnane

  2. Flexion shares soar 39% premarket

    7:04 a.m. Oct. 11, 2021

    - Ciara Linnane

  3. Tax Time Is Coming. How Stocks With Losses Offset Capital Gains.

    9:03 p.m. Oct. 10, 2021

    - Barron's Online

  4. Pacira BioSciences upgraded to overweight from neutral at J.P. Morgan

    7:54 a.m. July 26, 2021

    - Tomi Kilgore

  5. Biotech stocks are a buy — especially these 18 picks

    2:02 p.m. March 13, 2021

    - Michael Brush

  6. Pacira BioSciences started at buy with $60 stock price target at SunTrust RH

    8:33 a.m. Jan. 24, 2020

    - Tomi Kilgore

  7. Sachem Head Capital Says A Split-Up Eagle Will Fly

    9:30 p.m. July 12, 2019

    - Barron's Online

  8. Pacira Pharmaceuticals reiterated as sell at Stifel

    8:36 a.m. March 8, 2019

    - Ciara Linnane

  9. Resolute’s Resolve

    8:00 p.m. Oct. 26, 2018

    - Barron's Online

  10. Pacira Pharmaceuticals started at neutral with $47 stock price target at J.P. Morgan

    9:12 a.m. Dec. 18, 2017

    - Tomi Kilgore

  11. Loading more headlines...
/news/nonmarketwatch/company/us/pcrx

Other News on PCRX

  1. Why Pacira Biosciences Stock Sank Today

    3:56 p.m. Oct. 4, 2021

    - Motley Fool

  2. Pacira BioSciences: Attractive Capital Gain Odds Next 3 Months

    1:13 p.m. Sept. 17, 2021

    - Seeking Alpha

  3. Pacira Biosciences (PCRX) Investor Presentation - Slideshow

    10:24 a.m. Aug. 13, 2021

    - Seeking Alpha

  4. Pacira BioSciences nabs prelim July net product sales of $42.1M

    8:43 a.m. Aug. 10, 2021

    - Seeking Alpha

  5. 10-Q: PACIRA BIOSCIENCES, INC.

    11:39 a.m. Aug. 3, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  6. Pacira (PCRX) Q2 Earnings Surpass Estimates

    9:15 a.m. Aug. 3, 2021

    - Zacks.com

  7. Pacira BioSciences Q2 2021 Earnings Preview

    11:31 a.m. Aug. 2, 2021

    - Seeking Alpha

  8. Loading more headlines...

At a Glance

Pacira Biosciences, Inc.

5 Sylvan Way

Suite 300

Parsippany, New Jersey 07054

Phone

1 9732543560

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$429.65M

Net Income

$145.52M

2020 Sales Growth

2.0%

Employees

624.00

/news/pressrelease/company/us/pcrx

Press Releases on PCRX

  1. ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO

    8:00 a.m. Sept. 21, 2021

    - BusinessWire - BZX

  2. Loading more headlines...
Link to MarketWatch's Slice.